ES2040726T3 - Composiciones medicamentosas estabilizadas contra la oxidacion. - Google Patents

Composiciones medicamentosas estabilizadas contra la oxidacion.

Info

Publication number
ES2040726T3
ES2040726T3 ES198787115281T ES87115281T ES2040726T3 ES 2040726 T3 ES2040726 T3 ES 2040726T3 ES 198787115281 T ES198787115281 T ES 198787115281T ES 87115281 T ES87115281 T ES 87115281T ES 2040726 T3 ES2040726 T3 ES 2040726T3
Authority
ES
Spain
Prior art keywords
against oxidation
stabilized against
drug compositions
compositions stabilized
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787115281T
Other languages
English (en)
Inventor
Kuchi Sury Murthy
Michael Ray Harris
Gerard Clifford Hokanson
Robert George Reisch, Jr.
Mahdi Bakir Fawzi
Frank Stanley Waldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25445868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2040726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2040726T3 publication Critical patent/ES2040726T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA RESISTENCIA A LA OXIDACION Y LA ESTABILIDAD DEL COLOR DE ALGUNOS INHIBIDORES DE ACE SE HACEN OPTIMAS CUANDO SE FORMULAN CON UN ESTABILIZANTE Y POR LO MENOS UN LUBRICANTE O EXCIPIENTE.
ES198787115281T 1986-10-20 1987-10-19 Composiciones medicamentosas estabilizadas contra la oxidacion. Expired - Lifetime ES2040726T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/921,717 US4830853A (en) 1986-10-20 1986-10-20 Drug compositions stabilized against oxidation

Publications (1)

Publication Number Publication Date
ES2040726T3 true ES2040726T3 (es) 1993-11-01

Family

ID=25445868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787115281T Expired - Lifetime ES2040726T3 (es) 1986-10-20 1987-10-19 Composiciones medicamentosas estabilizadas contra la oxidacion.

Country Status (20)

Country Link
US (1) US4830853A (es)
EP (1) EP0264887B1 (es)
JP (1) JP2703906B2 (es)
KR (1) KR960000430B1 (es)
AT (1) ATE67090T1 (es)
AU (1) AU604061B2 (es)
CA (1) CA1297024C (es)
DE (1) DE3772924D1 (es)
DK (1) DK174916B1 (es)
ES (1) ES2040726T3 (es)
FI (1) FI100091B (es)
GR (1) GR3002698T3 (es)
HK (1) HK85694A (es)
IE (1) IE60773B1 (es)
NO (1) NO874352L (es)
NZ (1) NZ221954A (es)
PH (1) PH25582A (es)
PT (1) PT85942B (es)
SG (1) SG95494G (es)
ZA (1) ZA877132B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
US6300362B1 (en) * 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
DK2263660T3 (en) * 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
ES2242398T3 (es) 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US20050202081A1 (en) * 2002-01-15 2005-09-15 Deepak Bahl Stable pharmaceutical compositions comprising ace inhibitor(s)
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
EP1734931A2 (en) * 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
US8017168B2 (en) * 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
KR100808132B1 (ko) 2007-03-02 2008-02-29 고천일 음식물쓰레기 소멸처리장치
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
WO2012085249A2 (en) * 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2016015798A1 (en) 2014-07-31 2016-02-04 Pharmathen S.A. Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2017077425A1 (en) 2015-11-07 2017-05-11 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
WO2019140032A1 (en) 2018-01-11 2019-07-18 Meritage Pharma, Inc. Stable corticosteroid compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (es) * 1957-07-17
US3697641A (en) * 1970-01-02 1972-10-10 Gerhard W Ahrens Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
EP0045238B1 (en) * 1980-07-29 1986-10-01 Sanofi S.A. Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4442089A (en) * 1982-07-06 1984-04-10 E. R. Squibb & Sons, Inc. Method for treating glaucoma with topical or systemic ACE inhibitor compositions
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration

Also Published As

Publication number Publication date
DK543587D0 (da) 1987-10-16
FI100091B (fi) 1997-09-30
IE60773B1 (en) 1994-08-10
KR960000430B1 (ko) 1996-01-06
GR3002698T3 (en) 1993-01-25
AU604061B2 (en) 1990-12-06
PT85942B (pt) 1990-07-31
ZA877132B (en) 1989-04-26
DE3772924D1 (de) 1991-10-17
CA1297024C (en) 1992-03-10
DK174916B1 (da) 2004-02-23
PH25582A (en) 1991-08-08
PT85942A (en) 1987-11-01
DK543587A (da) 1988-04-21
AU7939787A (en) 1988-04-21
JP2703906B2 (ja) 1998-01-26
IE872550L (en) 1988-04-20
KR880004811A (ko) 1988-06-27
FI874594L (fi) 1988-04-21
JPS63104931A (ja) 1988-05-10
NZ221954A (en) 1990-03-27
SG95494G (en) 1994-10-28
FI874594A0 (fi) 1987-10-19
US4830853A (en) 1989-05-16
EP0264887A1 (en) 1988-04-27
HK85694A (en) 1994-08-26
ATE67090T1 (de) 1991-09-15
EP0264887B1 (en) 1991-09-11
NO874352D0 (no) 1987-10-19
NO874352L (no) 1988-04-21

Similar Documents

Publication Publication Date Title
ES2040726T3 (es) Composiciones medicamentosas estabilizadas contra la oxidacion.
ES2040231T3 (es) Composiciones medicamentosas estables.
ATE61582T1 (de) Styrylpyrazole, -isoxazole und analoga mit 5lipoxygenase-inhibitor-wirkung und pharmazeutische zusammensetzungen damit.
ES2061890T3 (es) Soluciones acuosas estabilizadas de 3-isotiazolinonas.
NO880950L (no) Fremstilling av oksygen med hoey renhet.
ZA88382B (en) Stabilized compositions
IE823053L (en) Piperazinylbenzisoxazoles and piperazinylbenzisothiazoles
IT1241430B (it) Limitatore del quantitativo di lubrificante.
MX9202935A (es) Derivados de 2,3-dihidro-1h-indeno y composicion farmaceutica que los contiene.
ES2043614T3 (es) Procedimiento para la preparacion de un compuesto bactericida.
MY103079A (en) New ophtalmological composition of matter
FI820994A7 (fi) Penisillaanihappo-1,1-dioksidin halometyyliestereiden (ja samansukuisten estereiden) valmistus.
DK578887A (da) Antihypertensiva
ES2058127T3 (es) Polipropilenos estabilizados contra la degradacion oxidativa con mezclas de diarilaminas substituidas con aralquilo y fenoles impedidos estericamente.
ES283591U (es) Una tableta de dosificacion farmaceutica adecuada para administracion oral
MX9202651A (es) Derivados de acido propenoico.
ES2054099T3 (es) Composicion estabilizada de interleucina-1-g(b).
GB1514151A (en) Piperidine derivatives
IT8421138A0 (it) Procedimento per la preparazione di miscele stabili di carbone e olio.
SU1432991A1 (ru) 4-Метил-5-(4-метилфениламино)-1,2,3-триазол, обладающий противовоспалительной активностью
IT8404259U1 (it) Contenitore provvisto di risalto antiforzamento del sigillo anti-sofisticazione.
IT8619331A0 (it) Soluzioni iniettabili stabili contenenti norfloxacina.
ES2065843A1 (es) Aplicacion de ent-11 , 16-dihidroxi-18-nor-4a -carboximetil-oxido de manoilo como inhibidor de la adenilatociclasa.
ATE55983T1 (de) Geschwefelte zusammensetzungen und schmiermittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 264887

Country of ref document: ES